Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
NasdaqGS - Nasdaq Real Time Price USD

Alkermes plc (ALKS)

Compare
28.54 +0.59 (+2.11%)
As of 2:48 PM EDT. Market Open.
Loading Chart for ALKS
DELL

Alkermes plc Overview Drug Manufacturers - Specialty & Generic / Healthcare

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

www.alkermes.com

2,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ALKS

View More

Performance Overview: ALKS

Trailing total returns as of 8/26/2024, which may include dividends or other distributions. Benchmark is

S&P 500
.

YTD Return

ALKS
2.88%
S&P 500
17.79%

1-Year Return

ALKS
5.04%
S&P 500
27.52%

3-Year Return

ALKS
6.88%
S&P 500
24.96%

5-Year Return

ALKS
42.20%
S&P 500
97.34%

Compare To: ALKS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ALKS

View More

Valuation Measures

Annual
As of 8/23/2024
  • Market Cap

    4.60B

  • Enterprise Value

    4.09B

  • Trailing P/E

    12.26

  • Forward P/E

    11.88

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.16

  • Price/Book (mrq)

    3.58

  • Enterprise Value/Revenue

    2.72

  • Enterprise Value/EBITDA

    10.48

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.15%

  • Return on Assets (ttm)

    8.62%

  • Return on Equity (ttm)

    30.08%

  • Revenue (ttm)

    1.51B

  • Net Income Avi to Common (ttm)

    385.71M

  • Diluted EPS (ttm)

    2.28

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    876.12M

  • Total Debt/Equity (mrq)

    28.66%

  • Levered Free Cash Flow (ttm)

    217.01M

Research Analysis: ALKS

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

21.00 Low
34.92 Average
28.54 Current
50.00 High
 

Company Insights: ALKS

People Also Watch